Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:73

Article

Menter, Alan¹  Thaci, Diamant²  Papp, Kim A.³  Wu, Jashin J.⁴  Bereswill, Mareike⁵  Teixeira, Henrique D.⁶  Rubant, Simone⁵  Williams, David A.⁶ 

[1] Baylor Univ, Med Ctr, Dallas, TX 75246 USA

[2] Univ Med Sch Schleswig Holstein, Comprehens Ctr Inflammat Med, Kiel, Germany

[3] Prob Med Res, Waterloo, ON, Canada

[4] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA

[5] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany

[6] AbbVie Inc, N Chicago, IL USA

关键词: adalimumab;    adverse events;    long-term safety;    malignancy;    registry;    serious infections;   

DOI  :  10.1016/j.jaad.2015.06.038

来源: Elsevier

【 摘 要 】

Background: ESPRIT is an ongoing, 10-year, observational registry, evaluating long-term safety and effectiveness of adalimumab treatment in routine clinical practice for patients with moderate to severe, chronic plaque psoriasis. Objectives: Initial 5-year results are reported. Methods: Two populations were analyzed: the all-treated population received 1 or more adalimumab doses in registry, continuing adalimumab treatment from a current prescription or previous study participation, and included the new-prescription population initiating adalimumab 4 weeks or earlier preregistry entry. Results: Data were collected from September 26, 2008, through November 30, 2013, for all-treated (n = 6059), which included new-prescription (n = 2580, 42.6%); median registry exposure was 765 and 677 days, respectively. In all-treated, rate (events per 100 patient-years of total adalimumab exposure [E/100PY]) of serious treatment-emergent adverse events (inside or outside of the registry) was 4.3 E/100PY, serious infection 1.0 E/100PY, malignancies 0.9 E/100PY (nonmelanoma skin cancers 0.6 E/100PY; melanomas <0.1 E/100PY). Standardized mortality ratio was 0.30 (95% confidence interval 0.19-0.44). Physician Global Assessment clear or minimal (effectiveness parameter) was achieved by 57.0% at 12 months and 64.7% at 60 months of treatment. Limitations: Observational data are subject to outcome-reporting bias. Conclusion: No new safety signals were observed with adalimumab treatment during this initial 5-year registry review. Observed number of deaths was below expected. As-observed effectiveness remained stable through 60 months.

【 授权许可】

Free